文献速递妇产影像US

孕36周母体血清糖基化纤连蛋白与血管生成标志物筛查子痫前期

Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-01-01

基于非干预筛查研究的病例对照研究,在35+0至36+6周检测母体血清GlyFn,比较其与MAP、UtA-PI、PlGF、sFlt-1等标志物组合对≥37周分娩PE和GH的预测性能。三联试验(危险因素+MAP+PlGF+sFlt-1)在10%假阳性率下对筛查后3周内PE的检出率为83.7%,加GlyFn未改善;作者认为GlyFn可能有用但需前瞻性验证。

要点

  • 35+0至36+6周筛查时,含MAP、PlGF、sFlt-1的三联试验对筛查后3周内PE检出率为83.7%(10%FPR)。
  • 三联试验加GlyFn未提高对PE的检出率,含MAP、UtA-PI、GlyFn的组合与三联试验性能相似。
  • 低PlGF或高sFlt-1/PlGF比值的筛查性能低于三联试验或含MAP、UtA-PI与GlyFn的组合。

核心结论

  • GlyFn可能是晚孕期筛查足月PE和GH的有用标志物,但本病例对照研究结果需前瞻性筛查研究验证。

研究设计与样本

  • 病例对照研究,样本来自单胎妊娠35+0至36+6周非干预筛查研究的储存样本,包括100例PE、100例GH和600例对照,均于≥37周分娩。

诊断标准与关键数值

  • 三联试验(母体危险因素+MAP+PlGF+sFlt-1)在10%FPR下,筛查后3周内PE检出率83.7%(95%CI 70.3-92.7%),筛查后任何时间PE检出率80.0%(95%CI 70.8-87.3%)。
  • 低PlGF浓度筛查在10%FPR下,3周内PE检出率65.3%(95%CI 50.4-78.3%),任何时间PE检出率56.0%(95%CI 45.7-65.9%)。
  • 高sFlt-1/PlGF比值筛查在10%FPR下,3周内PE检出率73.5%(95%CI 58.9-85.1%),任何时间PE检出率63.0%(95%CI 52.8-72.4%)。

临床应用与阅片要点

  • 作者认为GlyFn可能是晚孕期筛查足月PE和GH的有用标志物,但需前瞻性筛查研究验证。
  • 三联试验加GlyFn未改善PE检出率,含MAP、UtA-PI和GlyFn的组合与三联试验性能相似。
  • 低PlGF浓度或高sFlt-1/PlGF比值筛查PE的检出率低于三联试验或含MAP、UtA-PI与GlyFn的组合。

局限性

  • 本病例对照研究结果需前瞻性筛查研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: First, to examine the predictive performance of maternal serum glycosylated fibronectin (GlyFn) at 35 + 0 to 36 + 6 weeks' gestation in screening for delivery with pre-eclampsia (PE) and delivery with gestational hypertension (GH) at ≥ 37 weeks' gestation, both within 3 weeks and at any time after the examination. Second, to compare the predictive performance for delivery with PE and delivery with GH of various combinations of biomarkers, including GlyFn, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). Third, to compare the predictive performance for delivery with PE and delivery with GH by serum PlGF concentration, sFlt-1/PlGF concentration ratio and the competing-risks model with different combinations of biomarkers as above. Fourth, to compare the predictive performance of screening at 11 + 0 to 13 + 6 weeks vs 35 + 0 to 36 + 6 weeks for delivery with PE and delivery with GH at ≥ 37 weeks' gestation.

METHODS: This was a case-control study in which maternal serum GlyFn was measured in stored samples from a non-intervention screening study in singleton pregnancies at 35 + 0 to 36 + 6 weeks' gestation using a point-of-care device. We used samples from women who delivered at ≥ 37 weeks' gestation, including 100 who developed PE, 100 who developed GH and 600 controls who did not develop PE or GH. In all cases, MAP, UtA-PI, PlGF and sFlt-1 were measured during the routine visit at 35 + 0 to 36 + 6 weeks. We used samples from patients that had been examined previously at 11 + 0 to 13 + 6 weeks' gestation. Levels of GlyFn were transformed to multiples of the expected median (MoM) values after adjusting for maternal demographic characteristics and elements from the medical history. Similarly, the measured values of MAP, UtA-PI, PlGF and sFlt-1 were converted to MoM. The competing-risks model was used to combine the prior distribution of the gestational age at delivery with PE, obtained from maternal risk factors, with various combinations of biomarker MoM values to derive the patient-specific risks of delivery with PE. The performance of screening of different strategies was estimated by examining the detection rate (DR) at a 10% fixed false-positive rate (FPR) and McNemar's test was used to compare the DRs between the different methods of screening.

RESULTS: The DR, at 10% FPR, of screening by the triple test (maternal risk factors plus MAP, PlGF and sFlt-1) was 83.7% (95% CI, 70.3-92.7%) for delivery with PE within 3 weeks of screening and 80.0% (95% CI, 70.8-87.3%) for delivery with PE at any time after screening, and this performance was not improved by the addition of GlyFn. The performance of screening by a combination of maternal risk factors, MAP, PlGF and GlyFn was similar to that of the triple test, both for delivery with PE within 3 weeks and at any time after screening. The performance of screening by a combination of maternal risk factors, MAP, UtA-PI and GlyFn was similar to that of the triple test, and they were both superior to screening by low PlGF concentration (PE within 3 weeks: DR, 65.3% (95% CI, 50.4-78.3%); PE at any time: DR, 56.0% (95% CI, 45.7-65.9%)) or high sFlt-1/PlGF concentration ratio (PE within 3 weeks: DR, 73.5% (95% CI, 58.9-85.1%); PE at any time: DR, 63.0% (95% CI, 52.8-72.4%)). The predictive performance of screening at 35 + 0 to 36 + 6 weeks' gestation for delivery with PE and delivery with GH at ≥ 37 weeks' gestation was by far superior to screening at 11 + 0 to 13 + 6 weeks.

CONCLUSION: GlyFn is a potentially useful biomarker in third-trimester screening for term PE and term GH, but the findings of this case-control study need to be validated by prospective screening studies. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sokratous N, Wright A, Syngelaki A, et al. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation. Ultrasound Obstet Gynecol. 2024. PMID: 37724582. doi:10.1002/uog.27481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。